Triple-negative breast cancer: new treatment strategies in the era of precision medicine

doi:10.1007/s11427-020-1714-8

Review

. 2021 Mar;64(3):372-388.

doi: 10.1007/s11427-020-1714-8. Epub 2020 Aug 11.

Triple-negative breast cancer: new treatment strategies in the era of precision medicine

Song-Yang Wu^#¹, Hai Wang^#¹, Zhi-Ming Shao¹, Yi-Zhou Jiang²

Affiliations

¹ Department of Breast Surgery, Fudan University Shanghai Cancer Center; Key Laboratory of Breast Cancer in Shanghai, Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, 200032, China.
² Department of Breast Surgery, Fudan University Shanghai Cancer Center; Key Laboratory of Breast Cancer in Shanghai, Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, 200032, China. yizhoujiang@fudan.edu.cn.

^# Contributed equally.

PMID: 32803712
DOI: 10.1007/s11427-020-1714-8

Review

Triple-negative breast cancer: new treatment strategies in the era of precision medicine

Song-Yang Wu et al. Sci China Life Sci. 2021 Mar.

. 2021 Mar;64(3):372-388.

doi: 10.1007/s11427-020-1714-8. Epub 2020 Aug 11.

Authors

Song-Yang Wu^#¹, Hai Wang^#¹, Zhi-Ming Shao¹, Yi-Zhou Jiang²

Affiliations

¹ Department of Breast Surgery, Fudan University Shanghai Cancer Center; Key Laboratory of Breast Cancer in Shanghai, Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, 200032, China.
² Department of Breast Surgery, Fudan University Shanghai Cancer Center; Key Laboratory of Breast Cancer in Shanghai, Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, 200032, China. yizhoujiang@fudan.edu.cn.

^# Contributed equally.

PMID: 32803712
DOI: 10.1007/s11427-020-1714-8

Abstract

Triple-negative breast cancer (TNBC) remains the most aggressive cluster of all breast cancers, which is due to its rapid progression, high probabilities of early recurrence, and distant metastasis resistant to standard treatment. Following the advances in cancer genomics and transcriptomics that can illustrate the comprehensive profiling of this heterogeneous disease, it is now possible to identify different subclasses of TNBC according to both intrinsic signals and extrinsic microenvironment, which have a huge influence on predicting response to established therapies and picking up novel therapeutic targets for each cluster. In this review, we summarize basic characteristics and critical subtyping systems of TNBC, and particularly discuss newly found prospective targets and relevant medications, which were proved promising in clinical trials, thus shedding light on the future development of precision treatment strategies.

Keywords: molecular subtype; precision medicine; targeted therapy; triple-negative breast cancer.

PubMed Disclaimer

Cited by

Transcytosable Peptide-Paclitaxel Prodrug Nanoparticle for Targeted Treatment of Triple-Negative Breast Cancer.
Wang L, Zhao C, Lu L, Jiang H, Wang F, Zhang X. Wang L, et al. Int J Mol Sci. 2023 Feb 28;24(5):4646. doi: 10.3390/ijms24054646. Int J Mol Sci. 2023. PMID: 36902076 Free PMC article.
FSIP1 enhances the therapeutic sensitivity to CDK4/6 inhibitors in triple-negative breast cancer patients by activating the Nanog pathway.
Chen G, Sun L, Gu X, Ai L, Yang J, Zhang Z, Hou P, Wang Y, Ou X, Jiang X, Qiao X, Ma Q, Niu N, Xue J, Zhang H, Yang Y, Liu C. Chen G, et al. Sci China Life Sci. 2023 Dec;66(12):2805-2817. doi: 10.1007/s11427-023-2343-y. Epub 2023 Jul 14. Sci China Life Sci. 2023. PMID: 37460715
The molecular subtyping and precision medicine in triple-negative breast cancer---based on Fudan TNBC classification.
Weng L, Zhou J, Guo S, Xu N, Ma R. Weng L, et al. Cancer Cell Int. 2024 Mar 30;24(1):120. doi: 10.1186/s12935-024-03261-0. Cancer Cell Int. 2024. PMID: 38555429 Free PMC article. Review.
Pycnogenol's Dual Impact: Inducing Apoptosis and Suppressing Migration via Vascular Endothelial Growth Factor/Fibroblast Growth Factor Signaling Pathways in Breast Cancer Cells.
Somesh S, Rajanathadurai J, Perumal E. Somesh S, et al. Cureus. 2024 Jul 24;16(7):e65286. doi: 10.7759/cureus.65286. eCollection 2024 Jul. Cureus. 2024. PMID: 39184682 Free PMC article.
RGCC-mediated PLK1 activity drives breast cancer lung metastasis by phosphorylating AMPKα2 to activate oxidative phosphorylation and fatty acid oxidation.
Cheng S, Wan X, Yang L, Qin Y, Chen S, Liu Y, Sun Y, Qiu Y, Huang L, Qin Q, Cui X, Wu M, Liu M. Cheng S, et al. J Exp Clin Cancer Res. 2023 Dec 15;42(1):342. doi: 10.1186/s13046-023-02928-2. J Exp Clin Cancer Res. 2023. PMID: 38102722 Free PMC article.

See all "Cited by" articles

References

1. Adams, S., Diamond, J.R., Hamilton, E., Pohlmann, P.R., Tolaney, S.M., Chang, C.W., Zhang, W., Iizuka, K., Foster, P.G., Molinero, L., et al. (2019a). Atezolizumab plus nab-paclitaxel in the treatment of metastatic triple-negative breast cancer with 2-year survival follow-up. JAMA Oncol 5, 334–342. - PubMed
1. Adams, S., Gatti-Mays, M.E., Kalinsky, K., Korde, L.A., Sharon, E., Amiri-Kordestani, L., Bear, H., McArthur, H.L., Frank, E., Perlmutter, J., et al. (2019b). Current landscape of immunotherapy in breast cancer. JAMA Oncol 5, 1205.
1. Adams, S., Loi, S., Toppmeyer, D., Cescon, D.W., De Laurentiis, M., Nanda, R., Winer, E.P., Mukai, H., Tamura, K., Armstrong, A., et al. (2019c). Pembrolizumab monotherapy for previously untreated, PD-L1-positive, metastatic triple-negative breast cancer: cohort B of the phase II KEYNOTE-086 study. Ann Oncol 30, 405–411. - PubMed
1. Adams, S., Schmid, P., Rugo, H.S., Winer, E.P., Loirat, D., Awada, A., Cescon, D.W., Iwata, H., Campone, M., Nanda, R., et al. (2019d). Pembrolizumab monotherapy for previously treated metastatic triple-negative breast cancer: cohort A of the phase II KEYNOTE-086 study. Ann Oncol 30, 397–404. - PubMed
1. Afghahi, A., Purington, N., Han, S.S., Desai, M., Pierson, E., Mathur, M.B., Seto, T., Thompson, C.A., Rigdon, J., Telli, M.L., et al. (2018). Higher absolute lymphocyte counts predict lower mortality from early-stage triple-negative breast cancer. Clin Cancer Res 24, 2851–2858. - PubMed - PMC

Publication types

Actions

MeSH terms

Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
- Springer

[1] Adams, S., Diamond, J.R., Hamilton, E., Pohlmann, P.R., Tolaney, S.M., Chang, C.W., Zhang, W., Iizuka, K., Foster, P.G., Molinero, L., et al. (2019a). Atezolizumab plus nab-paclitaxel in the treatment of metastatic triple-negative breast cancer with 2-year survival follow-up. JAMA Oncol 5, 334–342. - PubMed

[2] Adams, S., Diamond, J.R., Hamilton, E., Pohlmann, P.R., Tolaney, S.M., Chang, C.W., Zhang, W., Iizuka, K., Foster, P.G., Molinero, L., et al. (2019a). Atezolizumab plus nab-paclitaxel in the treatment of metastatic triple-negative breast cancer with 2-year survival follow-up. JAMA Oncol 5, 334–342. - PubMed

[3] Adams, S., Gatti-Mays, M.E., Kalinsky, K., Korde, L.A., Sharon, E., Amiri-Kordestani, L., Bear, H., McArthur, H.L., Frank, E., Perlmutter, J., et al. (2019b). Current landscape of immunotherapy in breast cancer. JAMA Oncol 5, 1205.

[4] Adams, S., Gatti-Mays, M.E., Kalinsky, K., Korde, L.A., Sharon, E., Amiri-Kordestani, L., Bear, H., McArthur, H.L., Frank, E., Perlmutter, J., et al. (2019b). Current landscape of immunotherapy in breast cancer. JAMA Oncol 5, 1205.

[5] Adams, S., Loi, S., Toppmeyer, D., Cescon, D.W., De Laurentiis, M., Nanda, R., Winer, E.P., Mukai, H., Tamura, K., Armstrong, A., et al. (2019c). Pembrolizumab monotherapy for previously untreated, PD-L1-positive, metastatic triple-negative breast cancer: cohort B of the phase II KEYNOTE-086 study. Ann Oncol 30, 405–411. - PubMed

[6] Adams, S., Loi, S., Toppmeyer, D., Cescon, D.W., De Laurentiis, M., Nanda, R., Winer, E.P., Mukai, H., Tamura, K., Armstrong, A., et al. (2019c). Pembrolizumab monotherapy for previously untreated, PD-L1-positive, metastatic triple-negative breast cancer: cohort B of the phase II KEYNOTE-086 study. Ann Oncol 30, 405–411. - PubMed

[7] Adams, S., Schmid, P., Rugo, H.S., Winer, E.P., Loirat, D., Awada, A., Cescon, D.W., Iwata, H., Campone, M., Nanda, R., et al. (2019d). Pembrolizumab monotherapy for previously treated metastatic triple-negative breast cancer: cohort A of the phase II KEYNOTE-086 study. Ann Oncol 30, 397–404. - PubMed

[8] Adams, S., Schmid, P., Rugo, H.S., Winer, E.P., Loirat, D., Awada, A., Cescon, D.W., Iwata, H., Campone, M., Nanda, R., et al. (2019d). Pembrolizumab monotherapy for previously treated metastatic triple-negative breast cancer: cohort A of the phase II KEYNOTE-086 study. Ann Oncol 30, 397–404. - PubMed

[9] Afghahi, A., Purington, N., Han, S.S., Desai, M., Pierson, E., Mathur, M.B., Seto, T., Thompson, C.A., Rigdon, J., Telli, M.L., et al. (2018). Higher absolute lymphocyte counts predict lower mortality from early-stage triple-negative breast cancer. Clin Cancer Res 24, 2851–2858. - PubMed - PMC

[10] Afghahi, A., Purington, N., Han, S.S., Desai, M., Pierson, E., Mathur, M.B., Seto, T., Thompson, C.A., Rigdon, J., Telli, M.L., et al. (2018). Higher absolute lymphocyte counts predict lower mortality from early-stage triple-negative breast cancer. Clin Cancer Res 24, 2851–2858. - PubMed - PMC

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Triple-negative breast cancer: new treatment strategies in the era of precision medicine

Affiliations

Triple-negative breast cancer: new treatment strategies in the era of precision medicine

Authors

Affiliations

Abstract

Similar articles

Cited by

References

Publication types

MeSH terms

LinkOut - more resources

Full Text Sources

Abstract

Similar articles

Cited by

References

Publication types

MeSH terms

Related information

LinkOut - more resources

Full Text Sources